NCT04963855View on ClinicalTrials.gov

A Phase I Study of GT300 in Healthy Subjects

PHASE1UnknownINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 23, 2021

Primary Completion Date

February 15, 2022

Study Completion Date

March 15, 2022

Conditions
Lewy Body Disease
Interventions
DRUG

GT300

SIngle oral dose

DRUG

Microcrystalline cellulose

placebo

Sponsors
All Listed Sponsors
lead

Generian Pharmaceuticals, Inc.

INDUSTRY